Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer

Neal S Fedarko, A. Jain, A. Karadag, M. R. Van Eman, L. W. Fisher

Research output: Contribution to journalArticle

Abstract

Purpose: Histological studies have shown that the two sialoproteins, bone sialoprotein (BSP) and osteopontin (OPN), are induced in multiple types of cancer. We have recently found that these proteins are bound in serum to complement factor H and that the complex must be disrupted to generate free protein to measure their total levels. We hypothesized that measuring total BSP and OPN levels would provide informative markers for the detection of cancer. Experimental Design: As a proof of concept study, serum from patients with diagnosed breast, colon, lung, or prostate cancer (n = 20 for each type) as well as normal serum (n = 77) were analyzed using competitive ELISAs developed for BSP and OPN. Sensitivity, specificity, as well as positive and negative predictive values were determined for each sialoprotein and cancer type. The relationship between sensitivity and specificity was profiled by receiver operating characteristic curves. Results and Conclusions: Determined values for serum BSP in ng/ml were 285 ± 19 for prostate, 373 ± 19 for colon, 318 ± 18 for breast, 155 ± 11 for lung cancer sera, and 154 ± 13 for normal sera. Values of OPN in ng/ml were 653 ± 39 for prostate, 449 ± 22 for colon, 814 ± 53 for breast, 724 ± 33 for lung, and 439 ± 30 for normal sera. The assays provide a high degree of sensitivity and specificity that enables the detection of colon, breast, prostate, and lung cancer.

Original languageEnglish (US)
Pages (from-to)4060-4066
Number of pages7
JournalClinical Cancer Research
Volume7
Issue number12
StatePublished - 2001

Fingerprint

Integrin-Binding Sialoprotein
Osteopontin
Colonic Neoplasms
Lung Neoplasms
Prostatic Neoplasms
Breast Neoplasms
Serum
Sialoglycoproteins
Breast
Sensitivity and Specificity
Prostate
Colon
Complement Factor H
Neoplasms
ROC Curve
Proteins
Research Design
Enzyme-Linked Immunosorbent Assay
Lung

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Fedarko, N. S., Jain, A., Karadag, A., Van Eman, M. R., & Fisher, L. W. (2001). Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clinical Cancer Research, 7(12), 4060-4066.

Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. / Fedarko, Neal S; Jain, A.; Karadag, A.; Van Eman, M. R.; Fisher, L. W.

In: Clinical Cancer Research, Vol. 7, No. 12, 2001, p. 4060-4066.

Research output: Contribution to journalArticle

Fedarko, NS, Jain, A, Karadag, A, Van Eman, MR & Fisher, LW 2001, 'Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer', Clinical Cancer Research, vol. 7, no. 12, pp. 4060-4066.
Fedarko, Neal S ; Jain, A. ; Karadag, A. ; Van Eman, M. R. ; Fisher, L. W. / Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. In: Clinical Cancer Research. 2001 ; Vol. 7, No. 12. pp. 4060-4066.
@article{8fb95f96357349d9a722319f67ebfa12,
title = "Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer",
abstract = "Purpose: Histological studies have shown that the two sialoproteins, bone sialoprotein (BSP) and osteopontin (OPN), are induced in multiple types of cancer. We have recently found that these proteins are bound in serum to complement factor H and that the complex must be disrupted to generate free protein to measure their total levels. We hypothesized that measuring total BSP and OPN levels would provide informative markers for the detection of cancer. Experimental Design: As a proof of concept study, serum from patients with diagnosed breast, colon, lung, or prostate cancer (n = 20 for each type) as well as normal serum (n = 77) were analyzed using competitive ELISAs developed for BSP and OPN. Sensitivity, specificity, as well as positive and negative predictive values were determined for each sialoprotein and cancer type. The relationship between sensitivity and specificity was profiled by receiver operating characteristic curves. Results and Conclusions: Determined values for serum BSP in ng/ml were 285 ± 19 for prostate, 373 ± 19 for colon, 318 ± 18 for breast, 155 ± 11 for lung cancer sera, and 154 ± 13 for normal sera. Values of OPN in ng/ml were 653 ± 39 for prostate, 449 ± 22 for colon, 814 ± 53 for breast, 724 ± 33 for lung, and 439 ± 30 for normal sera. The assays provide a high degree of sensitivity and specificity that enables the detection of colon, breast, prostate, and lung cancer.",
author = "Fedarko, {Neal S} and A. Jain and A. Karadag and {Van Eman}, {M. R.} and Fisher, {L. W.}",
year = "2001",
language = "English (US)",
volume = "7",
pages = "4060--4066",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer

AU - Fedarko, Neal S

AU - Jain, A.

AU - Karadag, A.

AU - Van Eman, M. R.

AU - Fisher, L. W.

PY - 2001

Y1 - 2001

N2 - Purpose: Histological studies have shown that the two sialoproteins, bone sialoprotein (BSP) and osteopontin (OPN), are induced in multiple types of cancer. We have recently found that these proteins are bound in serum to complement factor H and that the complex must be disrupted to generate free protein to measure their total levels. We hypothesized that measuring total BSP and OPN levels would provide informative markers for the detection of cancer. Experimental Design: As a proof of concept study, serum from patients with diagnosed breast, colon, lung, or prostate cancer (n = 20 for each type) as well as normal serum (n = 77) were analyzed using competitive ELISAs developed for BSP and OPN. Sensitivity, specificity, as well as positive and negative predictive values were determined for each sialoprotein and cancer type. The relationship between sensitivity and specificity was profiled by receiver operating characteristic curves. Results and Conclusions: Determined values for serum BSP in ng/ml were 285 ± 19 for prostate, 373 ± 19 for colon, 318 ± 18 for breast, 155 ± 11 for lung cancer sera, and 154 ± 13 for normal sera. Values of OPN in ng/ml were 653 ± 39 for prostate, 449 ± 22 for colon, 814 ± 53 for breast, 724 ± 33 for lung, and 439 ± 30 for normal sera. The assays provide a high degree of sensitivity and specificity that enables the detection of colon, breast, prostate, and lung cancer.

AB - Purpose: Histological studies have shown that the two sialoproteins, bone sialoprotein (BSP) and osteopontin (OPN), are induced in multiple types of cancer. We have recently found that these proteins are bound in serum to complement factor H and that the complex must be disrupted to generate free protein to measure their total levels. We hypothesized that measuring total BSP and OPN levels would provide informative markers for the detection of cancer. Experimental Design: As a proof of concept study, serum from patients with diagnosed breast, colon, lung, or prostate cancer (n = 20 for each type) as well as normal serum (n = 77) were analyzed using competitive ELISAs developed for BSP and OPN. Sensitivity, specificity, as well as positive and negative predictive values were determined for each sialoprotein and cancer type. The relationship between sensitivity and specificity was profiled by receiver operating characteristic curves. Results and Conclusions: Determined values for serum BSP in ng/ml were 285 ± 19 for prostate, 373 ± 19 for colon, 318 ± 18 for breast, 155 ± 11 for lung cancer sera, and 154 ± 13 for normal sera. Values of OPN in ng/ml were 653 ± 39 for prostate, 449 ± 22 for colon, 814 ± 53 for breast, 724 ± 33 for lung, and 439 ± 30 for normal sera. The assays provide a high degree of sensitivity and specificity that enables the detection of colon, breast, prostate, and lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0035671826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035671826&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 4060

EP - 4066

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -